购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

Ambrisentan

Rating icon 很棒
产品编号 T1655Cas号 177036-94-1
别名 安倍生坦, LU 208075, BSF-208075, BSF 208075

Ambrisentan (BSF 208075) 是 ET A 型受体选择性拮抗剂。

Ambrisentan

Ambrisentan

Rating icon 很棒
纯度: 99.86%
产品编号 T1655 别名 安倍生坦, LU 208075, BSF-208075, BSF 208075Cas号 177036-94-1

Ambrisentan (BSF 208075) 是 ET A 型受体选择性拮抗剂。

规格价格库存数量
1 mg¥ 115现货
5 mg¥ 248现货
10 mg¥ 373现货
25 mg¥ 589现货
50 mg¥ 948现货
100 mg¥ 1,420现货
200 mg¥ 2,090现货
1 mL x 10 mM (in DMSO)¥ 273现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"Ambrisentan"的相关化合物库

选择批次:
纯度:99.86%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
Ambrisentan (BSF 208075) is an endothelin receptor antagonist used in the therapy of pulmonary arterial hypertension (PAH). Ambrisentan has been associated with a low rate of serum enzyme elevations during therapy but has yet to be implicated in cases of clinically apparent acute liver injury.
体内活性
Hepatic hydroxyproline content in the Ambrisentan group is significantly lower compared to the control group (18.0 μg/g±6.1 μg/g vs 33.9 μg/g±13.5 μg/g liver, respectively, P=0.014). Hepatic fibrosis estimated by Sirius red staining and areas positive for α-smooth muscle actin, indicative of activated hepatic stellate cells, are also significantly lower in the Ambrisentan group (0.46%±0.18% vs 1.11%±0.28%, respectively, P=0.0003; and 0.12%±0.08% vs 0.25%±0.11%, respectively, P=0.047). In addition, hepatic RNA expression levels of procollagen-1 and tissue inhibitor of metalloproteinase-1 (TIMP-1) are significantly lower by 60% and 45%, respectively, in the Ambrisentan group. Inflammation, steatosis, and endothelin-related mRNA expression in the liver are not significantly different between the groups. Ambrisentan attenuates the progression of hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing procollagen-1 and TIMP-1 gene expression. Ambrisentan did not affect inflammation or steatosis[6].
激酶实验
In vitro PTPase assays: Individual PTPases (0.01 μg/reaction) in 50 μL of PTPase buffer [50 mM Tris (pH 7.4)] are incubated at 22 ℃ for 10 min or as indicated in the absence or presence of inhibitory compounds. Substrates (0.2 mM phosphotyrosine peptide) are then added and allows to react at 22 ℃ for 18 hr. PTPase activity of individual reactions is measured by adding 100 μL of malachite green solution (UBI) and then quantifying the amounts of free phosphate cleaved by the PTPase from the peptide substrate by spectrometry (A660 nm). Relative PTPase activities are calculated based on the formula [(PTPase activity in the presence of an inhibitory compound)/(PTPase activity in the absence of the compound) × 100%]. Reactions performed under comparable conditions in the absence of recombinant PTPases only are used as controls and shows no detectable PTPase activity.
细胞实验
Ambrisentan is dissolved in DMSO and stored, and then diluted with appropriate medium before use. Unless otherwise stated, for each BMEC experiment cells are randomly divided into 4 groups: (1) normoxia vehicle control (Nx-CTRL); (2) normoxia-treated; (3) hypoxia (24 h) control (Hx-CTRL) and (4) hypoxia (24 h) treated. As previously described, Nrf2 activators are added 24 h prior to any hypoxic exposures. Cell treatments are; Protandim (100 μg/mL), methazolamide (125 μg/mL, nifedipine (7 μg/mL) or Ambrisentan (40 μg/mL). In addition, some cells are treated with Nrf2 siRNA. In these experiments, siRNA is added 24 h prior to drug treatments. The rationale for 24 h hypoxia exposure for BMEC is to ensure that cells remained transfected with siRNA for the pre-treatment of drugs (24 h in normoxia) and during the 24 h hypoxia exposure. Data is collected from at least three separate cell culture preparations on three separate days (n=9)[2].
别名安倍生坦, LU 208075, BSF-208075, BSF 208075
化学信息
分子量378.42
分子式C22H22N2O4
CAS No.177036-94-1
SmilesC([C@H](OC=1N=C(C)C=C(C)N1)C(O)=O)(OC)(C2=CC=CC=C2)C3=CC=CC=C3
密度1.228g/cm3
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
Ethanol: 6 mg/mL (15.9 mM)
DMSO: 45 mg/mL (118.92 mM)
溶液配制表
1mg5mg10mg50mg
1 mM2.6426 mL13.2128 mL26.4257 mL132.1283 mL
5 mM0.5285 mL2.6426 mL5.2851 mL26.4257 mL
10 mM0.2643 mL1.3213 mL2.6426 mL13.2128 mL
1mg5mg10mg50mg
20 mM0.1321 mL0.6606 mL1.3213 mL6.6064 mL
50 mM0.0529 mL0.2643 mL0.5285 mL2.6426 mL
100 mM0.0264 mL0.1321 mL0.2643 mL1.3213 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy Ambrisentan | purchase Ambrisentan | Ambrisentan cost | order Ambrisentan | Ambrisentan chemical structure | Ambrisentan in vivo | Ambrisentan formula | Ambrisentan molecular weight